Understand the source comparison
Glow Stack: Formulation Comparison
Subcutaneous Injection 70–95% for most peptides Minimal—peptide bypasses GI tract entirely None—standard bacteriostatic water reconstitution sufficient Standard research protocol dosing applies without adjustment This is the validated route for lyophilised res
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Subcutaneous Injection
- 70–95% for most peptides
- Minimal—peptide bypasses GI tract entirely
- None—standard bacteriostatic water reconstitution sufficient
- Standard research protocol dosing applies without adjustment
- This is the validated route for lyophilised research peptides—bioavailability is high and predictable
- Oral (Unmodified Peptide)
- <2%, often undetectable
- Begins within seconds in saliva; complete degradation within 60–90 min in stomach
- Requires enteric coating, absorption enhancers, or permeation modulators to achieve any measurable systemic levels
- Not applicable—insufficient absorption regardless of frequency
- Unmodified peptides like Glow Stack cannot achieve therapeutic plasma levels via oral route
- Oral (Modified Formulation)
- 1–5% with advanced pharmaceutical modifications
- Delayed by enteric coating; still subject to intestinal protease degradation
- Enteric coating + SNAC-type enhancers + sometimes structural peptide modification (e.g., lipidation or PEGylation)
- 10–50× higher dose required vs subcutaneous to achieve equivalent plasma concentration
- Requires pharmaceutical-grade formulation engineering—not feasible for standard research peptide use